Medilente Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
- Paid Up Capital ₹ 0.30 M
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.50 M
- Revenue Growth -37.33%
- Profit Growth 8.12%
- Ebitda 337.14%
- Net Worth 22.56%
- Total Assets -2.02%
About Medilente Pharma
Medilente Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 June 2013 and has a history of 11 years and seven months. Its registered office is in Chandigarh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.30 M.
The company currently has active open charges totaling ₹4.50 M.
Company Details
-
Location
Chandigarh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24232CH2013PTC034546
-
Company No.
034546
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Jun 2013
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
What products or services does Medilente Pharma Private Limited offer?
Medilente Pharma Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Third Party Manufacturing, Nutraceuticals & Dietary Supplements, Multivitamin Tablets & Capsules, Multivitamin Syrup & Drops, Common Disease Medicines, Psoriasis Ointment, Digestive System Drugs & Medicines, Antacid Drugs, Antihistamines.
Who are the key members and board of directors at Medilente Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohtas Sharma
|
Director | 21-Jan-2023 | Current |
|
Pragya Sharma
|
Director | 12-Jun-2013 | Current |
|
Nikhil Sharma
|
Additional Director | 25-Apr-2024 | Current |
Financial Performance of Medilente Pharma.
Medilente Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 37.33% decrease. The company also saw a slight improvement in profitability, with a 8.12% increase in profit. The company's net worth Soared by an impressive increase of 22.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medilente Pharma?
In 2023, Medilente Pharma had a promoter holding of 44.00% and a public holding of 56.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Tanishka Pharmaceuticals Private LimitedRohtas Sharma is a mutual person
-
Healthkind Labs Private LimitedPragya Sharma and Rohtas Sharma are mutual person
-
Healthserch Pharma LlpRohtas Sharma is a mutual person
-
Healthkynt Labs Private LimitedPragya Sharma and Rohtas Sharma are mutual person
Charges (Loans)
₹4.50 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.45 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Jun 2023 | Hdfc Bank Limited | ₹4.50 M | Open |
How Many Employees Work at Medilente Pharma?
Unlock and access historical data on people associated with Medilente Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medilente Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medilente Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
